Alzheimer's Disease Drugs Clinical Trials
(yielding late-stage clinical data)
Please Help Support Alzheimer's Research Today!
Your Alzheimer's donation will help billions live without it.
Scientists are making great strides toward developing new tests enabling the early diagnosis of Alzheimer's disease, perhaps even before patients start exhibiting the loss of memory and cognitive function that are the terrible hallmarks of the neuro-degenerative disease. Coming up with drugs to effectively treat or even reverse Alzheimer's is proving to be much a more elusive goal, unfortunately. Tuesday's announcement by Eli Lilly(LLY) that Alzheimer's patients treated with its experimental drug semagacestat were performing worse than placebo patients in two late-stage studies. (forcing Lilly to stop the studies) was just the latest in a string of negative results from Alzheimer's drug trials. Other recent Alzheimer's late-stage drug study failures have tripped up the partnership between Pfizer(PFE) and Medivation(MDVN), Myriad Genetics(MYGN) and the now-defunct Neurochem. A drug owned by Elan(ELN) and Wyeth (since bought by Johnson& Johnson(JNJ)) and another controlled by Elan and Transition Therapeutics(TTHI) are being studied in ongoing phase III studies despite what might be optimistically called mixed phase II results.
Long term, recently announced breakthroughs involving new brain imaging techniques and the discovery of biomarkers for Alzheimer's might allow scientists to learn more about the causes of Alzheimer's. Along with new diagnostics, the scientific consensus seems to be moving towards designing clinical trials that target patients in early-stage Alzheimer's patients, or even patients with pre-Alzheimer's, which may give drugs a better chance for success.
Meantime, drug companies forge ahead with Alzheimer's clinical trials. Perhaps one of the drugs listed below will succeed where so many others have failed. After Tuesday's bad news from Lilly, investors seeking Alzheimer's gold could use some cheering up. Read more: thestreet.com
Long term, recently announced breakthroughs involving new brain imaging techniques and the discovery of biomarkers for Alzheimer's might allow scientists to learn more about the causes of Alzheimer's. Along with new diagnostics, the scientific consensus seems to be moving towards designing clinical trials that target patients in early-stage Alzheimer's patients, or even patients with pre-Alzheimer's, which may give drugs a better chance for success.
Meantime, drug companies forge ahead with Alzheimer's clinical trials. Perhaps one of the drugs listed below will succeed where so many others have failed. After Tuesday's bad news from Lilly, investors seeking Alzheimer's gold could use some cheering up. Read more: thestreet.com
Fortified milk = healthier child development
A Fonterra funded study suggests that milk fortified with micronutrients, especially zinc and iron, can be an effective tool to alleviate nutrition deficiencies among young children. Read more: nutraingredients.com
No comments:
Post a Comment